13093-04-4

Basic information

• Product Name: N,N'-DIMETHYL-1,6-HEXANEDIAMINE
• Synonyms: n,n’-dimethyl-6-hexanediamine;1,6-BIS(METHYLAMINO)HEXANE;N,N'-DIMETHYLHEXAMETHYLENEDIAMINE;N,N'-DIMETHYL-1,6-DIAMINOHEXANE;N,N'-DIMETHYL-1,6-HEXANEDIAMINE;N,N'-dimethylhexane-1,6-diamine;1,6-Bis(methylamino)hexane, N,Nμ-Dimethyl-1,6-diaminohexane;1,6-Hexanediamine, N,N'-dimethyl-
• CAS NO: 13093-04-4
• Molecular Formula: C₈H₂₀N₂
• Molecular Weight: 144.26
• EINECS: 236-005-1
• Mol File: 13093-04-4.mol
• Article Data: 8

Chemical Properties

• Melting Point: 15-18 °C(lit.)
• Boiling Point: 96 °C14 mm Hg(lit.)
• Flash Point: 176 °F
• Appearance: /
• Density: 0.807 g/mL at 25 °C(lit.)
• Refractive Index: n20/D 1.447(lit.)
• Storage Temp.: Keep in dark place,Inert atmosphere,Room temperature
• PKA: 11.06±0.10(Predicted)
• BRN: 1735385
• CAS DataBase Reference: N,N'-DIMETHYL-1,6-HEXANEDIAMINE(CAS DataBase Reference)
• NIST Chemistry Reference: N,N'-DIMETHYL-1,6-HEXANEDIAMINE(13093-04-4)
• EPA Substance Registry System: N,N'-DIMETHYL-1,6-HEXANEDIAMINE(13093-04-4)

Safety Data

• Hazard Codes: Xi
• Statements: 36/37/38
• Safety Statements: 26-36
• RIDADR: 2735
• WGK Germany: 3
• HazardClass: 8
• PackingGroup: II
• Hazardous Substances Data: 13093-04-4(Hazardous Substances Data)

Usage

Uses

N,N′-Dimethyl-1,6-hexanediamine (DMHDA) can be used as an organic building block to synthesize: Hydroxyurethane by reacting with propylene carbonate.N,N′-dimethyl, N,N′-di(methacryloxy ethyl)-1,6-hexanediamine (NDMH), a monomer applicable as both a co-initiator and a reactive diluent for dental resins. Degradable poly(amino alcohol ester) polymer by nucleophilic addition with diglycidyl adipate for the potential use in gene transfection vectors.

Upstream product

• 629-03-8 1 ,6-dibromohexane 
• 74-89-5 methylamine 
• 629-09-4 1,6-diiodohexane 
• 16644-54-5 N,N'-bis(tert-butoxycarbonyl)-1,6-hexanediamine 
• 47473-92-7 N,N'-dibenzenesulfonyl-1,6-diaminohexane 
• 3009-40-3 N¹,N²-dibenzylidenehexane-1,6-diamine 
• 124-09-4 1,6-Hexanediamine 
• 67-56-1 methanol 
• 35161-65-0 hexanediyldiformamide 
• 111-69-3 hexanedinitrile 
• 80-48-8 methyl p-toluene sulfonate 
• 64-17-5 ethanol 
• 592-42-7 1,5-Hexadien 
• 75190-00-0 C₂₂H₃₀N₂⁽²⁺⁾*2CH₃O₄S^(1-) 

Downstream Products

• 93300-59-5 C₂₂H₂₈N₂O₂ 
• 101158-53-6 4,4′-[1,6-hexanediylbis(methylimino)]bisbenzaldehyde 
• 109-89-7 diethylamine 
• 110-89-4 piperidine 
• 111-49-9 hexamethylene imine 
• 74-89-5 methylamine 
• 109-05-7 2-Methylpiperidin 
• 157614-63-6 N-Benzyloxy-3-({6-[(2-benzyloxycarbamoyl-ethyl)-methyl-amino]-hexyl}-methyl-amino)-propionamide 
• 117688-88-7 N,N''-1,6-(hexanediyl)bis[N'-cyclohexyl-N'-[(cyclohexylimino)(4-morpholinyl)methyl]-N-methylurea] 
• 99191-71-6 N,N'-dimethyl-N,N'-hexanediyl-bis-carbamoyl chloride 

Relevant articles and documents

Inhibition of cellular proliferation and induction of apoptosis in human lung adenocarcinoma A549 cells by T-type calcium channel antagonist

The anti-proliferative and apoptotic activities of new T-type calcium channel antagonist, 6e (BK10040) on human lung adenocarcinoma A549 cells were investigated. The MTT assay results indicated that BK10040 was cytotoxic against human lung adenocarcinoma (A549) and pancreatic cancer (MiaPaCa2) cells in a dose-dependent manner with IC50 of 2.25 and 0.93 μM, respectively, which is ca. 2-fold more potent than lead compound KYS05090 despite of its decreased T-type calcium channel blockade. As a mode of action for cytotoxic effect of BK10040 on lung cancer (A549) cells, this cancer cell death was found to have the typical features of apoptosis, as evidenced by the accumulation of positive cells for annexin V. In addition, BK10040 triggered the activations of caspases 3 and 9, and the cleavages of poly (ADP-ribose) polymerase (PARP). Moreover, the treatment with z-VAD-fmk (a broad spectrum caspase inhibitor) significantly prevented BK10040-induced apoptosis. Based on these results, BK10040 may be used as a potential therapeutic agent for human lung cancer via the potent apoptotic activity.

Use of additive sites to control nitric oxide release from nitric oxide donors contained within polymers

A method for increasing, prolonging, and/or controlling the release rates of nitric oxide (NO) from polymeric materials containing NO adducts. Such NO-containing polymeric materials may find use in devices such as blood contacting devices, and biocompatible devices utilizing the same. The method and device utilizes anionic site additives, acidic site additives and/or acidic producing site additives in a polymer that contains NO-adducts to generate higher fluxes of NO to exceed NO threshold levels desirable to substantially prevent and/or minimize reactions such as platelet activation or adhesion.

Stereoselective aldol additions of achiral ethyl ketone-derived trichlorosilyl enolates

Methods for the preparation of geometrically defined enoxy(trichlorosilanes) derived from ethyl ketone enolates have been developed. The addition of enoxy(trichlorosilanes) (trichlorosilyl enolates) to aldehydes proceeds with good yields in the presence of catalytic amounts of chiral phosphoramides. The reaction of Z-trichlorosilyl enolates to aryl aldehydes affords aldol products with good to excellent diastereo- and enantioselectivities. Phosphoramide-catalyzed aldol additions lacked substrate generality providing modest selectivities with unsaturated and aliphatic aldehydes. In all cases, the phosphoramide-catalyzed aldol addition of E-trichlorosilyl enolates to aldehydes provided good yields with moderate to good stereoselectivities.